DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

DRG
  • Login
  • Products
    • Biopharma
      • Market Assessment
      • Multichannel Engagement Insights
      • Real-World Data
      • Market Access

      • Fingertip Formulary Suite
      • Managed Market Surveyor
      • Account Management Dashboard
      • U.S. Managed Markets Insights
      • Healthbase
      • Market Access Platform
      • Global Market Access Solution
    • Medtech
      • Market Insights
      • Procedure Finder
      • PriceTrack
  • Solutions
    • Solutions
      • Market Sizing and Forecasting
      • Commercial Effectiveness
      • Global Access Solutions
      • Multichannel Engagement Strategy
      • Integrated Patient Journey
      • Understanding Covered Lives
      • Learning Solutions
      • Biotech solutions
      • Medtech Solutions
      • Payer Solutions
      • Provider Solutions
    • Consulting Services
      • Consulting Services
      • HEOR & Value Communication
  • Find A Report
    • Market Assessment
    • Multichannel Engagement
    • Market Access
    • Medtech Insights
  • Events
    • Meet Us at These Events
  • DRG Perspectives
  • About Us
    • Our Company
    • About Clarivate
    • Newsroom
    • Careers
    • Contact us

DRG and its group companies would like to inform you that we have updated our website privacy policy.

Acknowledge
Home › DRG Perspectives › U.S. payers are warming up to...
U.S. payers are warming up to covering digital therapeutics

Multichannel Payer Marketing 2020

70% of formulary decision-makers cover or are interested in covering digital therapeutics

Increasingly sophisticated and often clinically-validated digital health tools and therapeutics (DTx) are coming to market. However, in the fragmented U.S. market, a big potential barrier remains: the question of who will pay for them. Study data suggest payers are warming to this emerging field of technologies.

Decision Resources Group surveyed 157 U.S. P&T committee members and found that nearly half agree that “Digital therapeutics are the future of healthcare.” Among these healthcare executives, who make formulary decisions within hospitals, IDNs, MCOs and PBMs, 25% said their organization currently provides coverage for DTx, and another 45% expressed interest in providing coverage.

Coverage, or openness to cover, medical mobile apps/digital therapeutics:

Digital therapeutics coverage was reported at higher levels among P&T committee members in IDNs that offer their own plans, along with MCOs and PBMs offering plans through:

Employers
31%

Health Exchanges
31%

Among all U.S. P&T committee members in IDN+s, MCOs, and PBMs

Those offering Medicare PDP demonstrated the highest level of interest in covering DTx (56%).

Among all U.S. P&T committee members

Source: Multichannel Payer Marketing 2020

Openness to digital therapeutics (DTx) coverage by health plans offered:

Among all U.S. P&T committee members in IDN+s, MCOs, and PBMs

Source: Multichannel Payer Marketing 2020

Physicians and patients may follow payers lead

Growing receptiveness among formulary decision-makers could boost interest in DTx among physicians. In the U.S., 44% of physicians express interest in prescribing medical apps for patients. Among physicians who are active P&T committee members, that interest climbs to 52%.

Some manufacturers of digital health tools have explored direct-to-consumer commercial models, but DRG studies show little consumer appetite for this – of the 22% of U.S. adults who are interested in using DTx to manage or treat health conditions, 1 in 5 say they would pay for it just as they would any other medication, while another 22% of those interested in DTx expect their insurance to cover digital treatments just as it would a traditional prescription medication.

Big insurers move towards greater reimbursement of digital therapeutics (DTx)

Towards the end of 2019, DRG analysts showed major shifts in the reimbursement landscape, as two major PBMs comprising a combined 53% market share in the U.S. adapted to facilitate DTx in health plans:

CVS Caremark unveiled a platform enabling payers to formalize and streamline the process for DTx reimbursement and distribution, allowing health plan clients to access negotiated pricing, verify member eligibility, and navigate the payments process.

Express Scripts announced that DTx solutions would be added to its digital health "formulary." The categorization of DTx into coverage tiers, much like traditional medicines, aims to protect health plans from higher costs while providing better access to these novel solutions.

In addition, Blue Cross Blue Shield, Medicaid, Highmark Health and Competitive Health added digital solutions to their benefits lists. Notably, Medicaid and Highmark have expanded coverage for tools beyond traditional therapeutic area indications (e.g., mental health or diabetes) to include novel digital tools for precision prenatal/postpartum care and cardiac rehab respectively. Findings from DRG’s Multichannel Payer Marketing study revealed that P&T committee members who have voted for, or advised on, new prescription medications or indications related to cardiovascular disorders are more interested in providing coverage for DTx compared to those voting/advising on other therapeutic areas.

As DTx gains traction among P&T committee members, physicians, and patients, more opportunities emerge for pharma to collaborate with big tech and health plans on digital-centric solutions. Completing the virtuous circle, these strategic partnerships can also encourage favorable formulary placement as payers begin to recognize the clinical and cost efficacy associated with digital health tools.

Biopharma Digital Health Multichannel Customer Engagement Infographics

Voice Tech is Already Changing How We Get Rx Info

View Now
DRG

Decision Resources Group

DRG is the premier provider of healthcare analytics, data and insight products and services to the world’s leading pharma, biotech and medical technology companies.

Read More

Company

  • About DRG
  • Careers
  • Offices
  • Locations

Resources

  • Sitemap
  • Newsroom
  • Whitepapers
  • Events
  • Reports

Support

  • Client Portal

Social

  • Linkedin
  • Facebook
  • Twitter
  • Youtube
  • Contact Us
  • Privacy & Cookies
  • Term of Use
  • Privacy Center
  • 2020 DR/Decision Resources, LLC
  • Find a Report
  • Linkedin
  • Twitter
  • Contact Us
Thank you for your ebook download,
and live webinar registration.

Don’t forget to attend on Jan. 19!

Close